expert roundtables

Choosing Between Thrombopoietin Receptor Agonists as Second-line Therapy in Chronic Immune Thrombocytopenia
Hematology

Choosing Between Thrombopoietin Receptor Agonists as Second-line Therapy in Chronic Immune Thrombocytopenia

expert roundtables
By Adam Cuker, MD, MS; Howard A. Liebman, MD; Terry B. Gernsheimer, MD
Mechanisms Contributing to the Pathophysiology of Immune Thrombocytopenia
Hematology

Mechanisms Contributing to the Pathophysiology of Immune Thrombocytopenia

expert roundtables
By Adam Cuker, MD, MS; Howard A. Liebman, MD; Terry B. Gernsheimer, MD
Identifying Patients With Immune Thrombocytopenia at Risk of Life-threatening Bleeding
Hematology

Identifying Patients With Immune Thrombocytopenia at Risk of Life-threatening Bleeding

expert roundtables
By Adam Cuker, MD, MS; Howard A. Liebman, MD; Terry B. Gernsheimer, MD
Treatment of Refractory Immune Thrombocytopenia
Hematology

Treatment of Refractory Immune Thrombocytopenia

expert roundtables
By Adam Cuker, MD, MS; Howard A. Liebman, MD; Terry B. Gernsheimer, MD
Corticosteroids as the Mainstay of First-line Treatment in Immune Thrombocytopenia
Hematology

Corticosteroids as the Mainstay of First-line Treatment in Immune Thrombocytopenia

expert roundtables
By Adam Cuker, MD, MS; Howard A. Liebman, MD; Terry B. Gernsheimer, MD
Load More